The effects of bestatin on humoral response to sheep erythrocytes in non-treated and cyclophosphamide-immunocompromised mice

References

• Mathé, G., Blazsek, I., Canon, C., Gil-Delgado, M., Misset, J.L. From experimental to clinical attempts in immunorestoration with bestatin and zinc. Comp Immunol Microbiol Infect Dis 1986, 9, 241–252.
   PubMed Web of Science ®Google Scholar
• Müller, W.E., Zahn, R.K., Arendes, J., Munsch, N., Umezawa, H. Activation of DNA metabolism in T-cells by bestatin. Biochem Pharmacol 1979, 28, 3131–3137.
   PubMed Web of Science ®Google Scholar
• Suda, H., Takita, T., Aoyagi, T., Umezawa, H. The structure of bestatin. J Antibiot 1976, 29, 100–101.
   PubMed Web of Science ®Google Scholar
• Umezawa, H., Ishizuka, M., Aoyagi, T., Takeuchi, T. Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot 1976, 29, 857–859.
   PubMed Web of Science ®Google Scholar
• Schorlemmer, H.U., Bosslet, K., Sedlacek, H.H. Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes. Cancer Res 1983, 43, 4148–4153.
   PubMed Web of Science ®Google Scholar
• Abe, F., Schneider, M., Black, P.L., Talmadge, J.E. Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice. Cancer Immunol Immunother 1989, 29, 231–236.
   PubMed Web of Science ®Google Scholar
• Yamagishi, H., Naito, K., Ueda, Y., Itoi, S., Kohnosu, H., Kobayashi, M., Kubo, H., Matsuda, A., Oka, T. Bestatin administration and the change in cellular immunity. Biomed Pharmacother 1991, 45, 117–120.
   PubMed Web of Science ®Google Scholar
• Harada, Y., Kajiki, A., Higuchi, K., Ishibashi, T., Takamoto, M. The mode of immunopotentiating action of bestatin: enhanced resistance to Listeria monocytogenes infection. J Antibiot 1983, 36, 1411–1414.
   PubMed Web of Science ®Google Scholar
• Pulido-Cejudo, G., Conway, B., Proulx, P., Brown, R., Izaguirre, C.A. Bestatin-mediated inhibition of leucine aminopeptidase may hinder HIV infection. Antiviral Res 1997, 36, 167–177.
   PubMed Web of Science ®Google Scholar
• Sasaki, S., Fukushima, J., Hamajima, K., Ishii, N., Tsuji, T., Xin, K.Q., Mohri, H., Okuda, K. Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1. Clin Exp Immunol 1998, 111, 30–35.
   PubMed Web of Science ®Google Scholar
• Aoyagi, K., Itoh, N., Abe, F., Abe, S., Uchida, K., Ishizuka, M., Takeuchi, T., Yamaguchi, H. Enhancement by ubenimex (bestatin) of host resistance to Candida albicans infection. J Antibiot 1992, 45, 1778–1784.
   PubMed Web of Science ®Google Scholar
• Hirayama, Y., Sakamaki, S., Takayanagi, N., Tsuji, Y., Sagawa, T., Chiba, H., Matsunaga, T., Niitsu, Y. [Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients–effects, complications and long-term survival]. Gan To Kagaku Ryoho 2003, 30, 1113–1118.
   PubMedGoogle Scholar
• Ota, K., Uzuka, Y. Clinical trials of bestatin for leukemia and solid tumors. Biotherapy 1992, 4, 205–214.
   PubMedGoogle Scholar
• Dunlap, B.E., Dunlap, S.A., Rich, D.H. Effect of bestatin on in vitro responses of murine lymphocytes to T-cell stimuli. Scand J Immunol 1984, 20, 237–245.
   PubMed Web of Science ®Google Scholar
• Weissmann, N., Leyhausen, G., Maidhof, A., Tanaka, W., Umezawa, H., Müller, W.E. Mitogenic potentials of bestatin, amastatin, arphamenines A and B, FK-156 and FK-565 on spleen lymphocytes. J Antibiot 1985, 38, 772–778.
   PubMed Web of Science ®Google Scholar
• Blomgren, H., Strender, L.E., Edsmyr, F. Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study. Biomedicine 1980, 32, 178–185.
   PubMedGoogle Scholar
• Iwahashi, M., Tanimura, H., Yamaue, H., Tsunoda, T., Tani, M., Noguchi, K., Mizobata, S., Tamai, M., Hotta, T., Arii, K. In vitro augmentation of cytotoxic activity of peripheral blood lymphocytes and spleen cells of cancer patients by ubenimex. Anticancer Res 1994, 14, 1557–1562.
   PubMed Web of Science ®Google Scholar
• Jarstrand, C., Blomgren, H. Bestatin, a new immunomodulator, enhances migration and phagocytosis of human granulocytes in vitro. J Clin Lab Immunol 1981, 5, 67–69.
   PubMedGoogle Scholar
• Lkhagvaa, B., Tani, K., Sato, K., Toyoda, Y., Suzuka, C., Sone, S. Bestatin, an inhibitor for aminopeptidases, modulates the production of cytokines and chemokines by activated monocytes and macrophages. Cytokine 2008, 44, 386–391.
   PubMed Web of Science ®Google Scholar
• Okura, A., Ishizuka, M., Takeuchi, T. Effect of ubenimex on the production of murine interferon. J Antibiot 1988, 41, 261–263.
   PubMed Web of Science ®Google Scholar
• Noma, T., Klein, B., Cupissol, D., Yata, J., Serrou, B. Increased sensitivity of IL2-dependent cultured T cells and enhancement of in vitro IL2 production by human lymphocytes treated with Bestatin. Int J Immunopharmacol 1984, 6, 87–92.
   PubMed Web of Science ®Google Scholar
• Shibuya, K., Hayashi, E., Abe, F., Takahashi, K., Horinishi, H., Ishizuka, M., Takeuchi, T., Umezawa, H. Enhancement of interleukin 1 and interleukin 2 releases by ubenimex. J Antibiot 1987, 40, 363–369.
   PubMed Web of Science ®Google Scholar
• Ishizuka, M., Masuda, T., Kanbayashi, N., Fukasawa, S., Takeuchi, T., Aoyagi, T., Umezawa, H. Effect of bestatin on mouse immune system and experimental murine tumors. J Antibiot 1980, 33, 642–652.
   PubMed Web of Science ®Google Scholar
• Abe, F., Matsuda, A., Schneider, M., Talmadge, J.E. Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice. Cancer Immunol Immunother 1990, 32, 75–80.
   PubMed Web of Science ®Google Scholar
• Shibuya, K., Chiba, S., Hino, M., Kitamura, T., Miyagawa, K., Takaku, F., Miyazano, K. Enhancing effect of ubenimex (bestatin) on proliferation and differentiation of hematopoietic progenitor cells, and the suppressive effect on proliferation of leukemic cell lines via peptidase regulation. Biomed Pharmacother 1991, 45, 71–80.
   PubMed Web of Science ®Google Scholar
• Bauvois, B., Dauzonne, D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev 2006, 26, 88–130.
   PubMed Web of Science ®Google Scholar
• Kuramochi, H., Motegi, A., Iwabuchi, M., Takahashi, K., Horinishi, H., Umezawa, H. Action of ubenimex on aminopeptidase activities in spleen cells and peritoneal macrophages from mice. J Antibiot 1987, 40, 1605–1611.
   PubMed Web of Science ®Google Scholar
• Suda, H., Aoyagi, T., Takeuchi, T., Umezawa, H. Inhibition of aminopeptidase B and leucine aminopeptidase by bestatin and its stereoisomer. Arch Biochem Biophys 1976, 177, 196–200.
   PubMed Web of Science ®Google Scholar
• Look, A.T., Ashmun, R.A., Shapiro, L.H., Peiper, S.C. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 1989, 83, 1299–1307.
   PubMed Web of Science ®Google Scholar
• Mishell, R.I., Dutton, R.W. Immunization of dissociated spleen cell cultures from normal mice. J Exp Med 1967, 126, 423–442.
   PubMed Web of Science ®Google Scholar
• Hudson, L., Hay, F.C. (1970). Practical Immunology. Oxford London, Edinburgh, Boston, Melbourne: Blackwell Scientific Publications, 247–250.
   Google Scholar
• Hemendinger, R.A., Bloom, S.E. Selective mitomycin C and cyclophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo. Immunopharmacology 1996, 35, 71–82.
   PubMed Web of Science ®Google Scholar
• Misra, R.R., Bloom, S.E. Roles of dosage, pharmacokinetics, and cellular sensitivity to damage in the selective toxicity of cyclophosphamide towards B and T cells in development. Toxicology 1991, 66, 239–256.
   PubMed Web of Science ®Google Scholar
• Willers, J.M., Sluis, E. The influence of cyclophosphamide on antibody formation in the mouse. Ann Immunol (Paris) 1975, 126, 267–279.
   PubMedGoogle Scholar
• Knoblich, A., Müller, W.E., Harle-Grupp, V., Falke, D. Enhancement of antibody formation against herpes simplex virus in mice by the T-cell mitogen bestatin. J Gen Virol 1984, 65 (Pt 10), 1675–1686.
   PubMedGoogle Scholar
• Morikawa, K., Morikawa, S., Nakano, A., Oseko, F. Bestatin, an inhibitor of aminopeptidase B, suppresses the proliferation and differentiation of human B-cells in vitro. Int J Immunopharmacol 1989, 11, 905–913.
   PubMed Web of Science ®Google Scholar